Shire Provides Results For Phase 3b Vyvanse Study

Anonymous User | Login

Published: 01-Jul-2009

Vyvanse improved the ability to focus and organize, as well as hyperactivity and impulsivity

Shire has announced the results of Phase 3b study of Vyvanse (lisdexamfetamine dimesylate) CII that showed significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Vyvanse is currently approved by the FDA for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.

The study supports the results of a previous phase 3 clinical trial in adults in which once-daily Vyvanse significantly improved ADHD symptoms of inattention, such as the ability to focus and organize, as well as hyperactivity and impulsivity.

Michael Yasick, Senior Vice President of ADHD Business Unit at Shire, said: This study provides important information for physicians about the effect of treatment with VYVANSE throughout the day in adults.

“We are proud to have evaluated VYVANSE in adults in this workplace-like environment.”

Genzyme Posts Net Income Of $195.5 Million For Q1 2009

Genzyme Corporation (Genzyme), a US-based medical devices company, has reported total revenues of $1.15 billion for the first quarter of 2009, up 4%, compared with the re ...

Simbionix And J&J Sign Distribution Agreement For Russia And The CIS Countries

Simbionix USA Corp. (Simbionix), a developer of medical simulation systems, has signed distribution agreement with Johnson & Johnson LLC (J&J), a subsidiary of Johnson & ...

Genzyme Reports 2008 Results

Genzyme Corporation (Genzyme) has reported total revenues of $4.6 billion for the full year of 2008, up 21%, compared with the revenues of $3.8 billion in the previous ye ...

Genzyme Reports Preliminary 2008 Results

Genzyme Corporation (Genzyme) has reported its preliminary 2008 results. It has reported estimated revenue of $4.6 billion for the full year 2008, compared with the reven ...

Lilly, Medtronic Form Strategic Marketing Alliance

Eli Lilly and Company (Lilly) and Medtronic entered into a strategic marketing alliance to strengthen their partnership in the US, in treating diabetic patients to manage ...

Cholesterol Drug Mipomersen' Trial Attains Objective

Genzyme and Isis Pharmaceuticals have reported positive Phase III clinical trial results for their cholesterol-controlling drug, mipomersen. Genzyme is now planning to su ...

Eli Lilly Launches Two Global Trials For Alzheimer’s Disease

Eli Lilly and Company is going to start enrolling patients for two separate but identical Phase III clinical trials of solanezumab(i), an anti-amyloid beta monoclonal ant ...

Johnson & Johnson Acquires Cougar For $1b

Johnson & Johnson (J&J) has acquired Los Angeles-based biopharmaceutical company, Cougar Biotechnology for approximately $1 billion in a cash tender offer. Cougar will wo ...

Eli Lilly Receives Positive Opinion For Alimta

Eli Lilly has declared that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion for the use of Alimta (pe ...

Summit, Biomarin Restructures Muscular Dystrophy Agreement

Summit and BioMarin have restructured their agreement for the Duchenne muscular dystrophy (DMD) program, under which Summit received an equity investment of $7 million at ...

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://www.pharmaceutical-business-review.com/news/shire_provides_results_for_phase_3b_vyvanse_study_090701/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Solutions4Science

Temperature Mapping and Validation Services ...

Exploristics

Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Sta...

NeuroProof

Screening Services for Pre-Clinical Development of Neuro-Pharmaceuticals and Safety Pharmacology ...

DASGIP

Parallel Bioreactor Systems for the Cultivation of Bacterial, Phototrophic, Animal and Human Cells ...

BioKinetic Europe

Phase I/II Contract Research Organisation ...

Toxikon Europe

CRO Providing Preclinical Safety Studies for the Life Science Community ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BioMarin) is principally engaged in the development and c ...

Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. (Barr) is engaged in the development, manufacturing and mark ...

Schering-Plough Corporation

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Celgene Corporation

Celgene Corporation (Celgene) is an integrated biopharmaceutical company. It is princi ...

Cortex Pharmaceuticals, Inc.

Cortex Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, d ...

Suppliers Product News

BioKinetic Showcasing Services at Key Industry Events in 2010

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750